Colleen Hanrahan, PhD; Mark Nicol, MD; Wendy Susan Stevens, MD
Editor in Chief: Ian M. Sanne, MBBCH, FCP(SA) (More Info)
Last Reviewed: July 8, 2016 (What's New)
inPractice® Africa’s Continuing Education Unit (CEU) provider, the South African Medical Association, offers physicians 3 CPD points on a 70% pass rate for completing this individual module. Nonphysicians who successfully complete the module will receive a participation certificate. To learn more on CPD credits and participation certificates, click here.
The World Health Organisation (WHO) 2015 Global Report[WHO Global TB 2015] estimated that there were 9.6 million new tuberculosis (TB) cases and 1.2 million deaths due to TB worldwide in 2014, of which 33% of TB deaths occurred in HIV-positive individuals. In 2014 in South Africa, TB incidence was 834 per 100,000 people and TB mortality was 44 per 100,000 people; this translates to 450,000 new cases and 24,000 deaths.[WHO Global TB 2015; WHO TB Fact Sheet ZA 2016] The incidence rate among HIV-positive individuals was 509 per 100,000 in 2014,[WHO TB Fact Sheet ZA 2016] which shows that the South African TB epidemic is fuelled by the concurrent HIV epidemic. South Africa has the largest burden of HIV-infected individuals worldwide (6.8 million in 2014). In 2014, WHO estimated that 61% of new TB cases in South Africa were coinfected with HIV.[WHO Global TB 2015] Tuberculosis is the leading killer of HIV-positive people worldwide and South Africa is no exception.[WHO TB Fact Sheet 2016]
For more information from inPractice on the trends in HIV and TB infection in South Africa, click here.
Added to this pandemic is the emergence of drug-resistant strains of Mycobacterium tuberculosis. South Africa is ranked as a high-burden country for multidrug-resistant tuberculosis (MDR-TB), which is resistance to both isoniazid and rifampicin, 2 of the most potent first-line anti-TB drugs. In 2014, 18,734 laboratory-confirmed cases of MDR-TB were reported in South Africa, representing 1.8% of all newly identified TB cases and 6.7% of all retreatment cases.[WHO Global TB 2015] This is likely an underestimate of the true level. HIV coinfection is common among South African patients with MDR-TB. A national cohort in 2011 found that 38% of patients with MDR-TB were infected with HIV.[Farley 2011] Mortality among HIV-infected individuals with MDR-TB is known to be high. In the national cohort of patients with MDR-TB, HIV-infected patients had twice the mortality risk of HIV-uninfected patients.[Farley 2011]
It remains unclear, however, whether HIV infection is a risk factor for MDR-TB.[Suchindran 2009] As high HIV rates drive the TB epidemic in South Africa, the dramatic increase in the TB caseload can overwhelm the TB control program, exacerbating the problem of MDR-TB.[Wells 2007] South Africa was the site of the first documented outbreak of extensively drug-resistant TB (resistant to all first- and second-line drugs), in which HIV coinfection was present in 100% of those tested, and mortality was 98%.[Gandhi 2006] Results from the first national TB drug-resistance survey in more than a decade will be presented in 2016 and should provide an updated understanding of the prevalence of MDR-TB in South Africa.
For more information from inPractice on drug-resistant TB, please click here.
Please help us evaluate this program by answering the following question(s). The correct answer will not be shown yet, but as you read on you’ll be asked the same question again, and then the correct answer will be displayed.